about
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cellsA Pin1/mutant p53 axis promotes aggressiveness in breast cancerA Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasisThe prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancerPSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical modelsPeritoneal tumor carcinomatosis: pharmacological targeting with hyaluronan-based bioconjugates overcomes therapeutic indications of current drugsDrug conjugation to hyaluronan widens therapeutic indications for ovarian cancerIn situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells.A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disordersSHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors.Quantitative imaging of the T cell antitumor response by positron-emission tomography.Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).Differential down-modulation of HLA class I and II molecule expression on human tumor cell lines upon in vivo transfer.A novel orally active water-soluble inhibitor of human glutathione transferase exerts a potent and selective antitumor activity against human melanoma xenografts.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersAutologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastasesThe mitochondrial calcium uniporter regulates breast cancer progression via HIF-1α.A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells.Fast method for skeletal tissue gene expression analysis.HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness.Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.Induction of Expandable Tissue-Specific Stem/Progenitor Cells through Transient Expression of YAP/TAZ.Retinoids as critical modulators of immune functions: new therapeutic perspectives for old compounds.Glutathione transferases as targets for cancer therapy.Glucocorticoid receptor signalling activates YAP in breast cancer.Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast.Fighting Viral Infections and Virus-Driven Tumors with Cytotoxic CD4+ T Cells.Immunotherapy for EBV-associated malignancies.Optical and multimodal peptide-based probes for in vivo molecular imaging.Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone.The nitrobenzoxadiazole derivative MC3181 blocks melanoma invasion and metastasisMelanoma targeting with [99mTc(N)(PNP3)]-labeled α-melanocyte stimulating hormone peptide analogs: Effects of cyclization on the radiopharmaceutical properties.Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy.Reverse immunoediting: When immunity is edited by antigen.Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth.
P50
Q24296824-D9770D4F-EB24-473A-BA52-1715F3A99274Q24312083-12EAF6A5-B91D-4F38-95AB-B2370DE2342CQ24312492-967BA368-CADB-475B-819A-75EF8C021E85Q24317638-A7879920-B2C9-4702-896C-6ACE46090CD2Q27339832-90AF3C45-0B8A-48B0-9D43-DF8690297B67Q28544821-5B9E4823-3C64-4FD5-8815-41E7F209DB04Q28648402-E72D88CB-81CF-45E9-B27F-F6DAC45152B5Q30976047-CB2B1BEA-30AC-49F8-9482-4E1B81AADC23Q33632095-D767F6DC-2747-4E4B-B0E0-41D4C190E562Q33696192-283FBDEA-26E5-428F-A2DC-B83CD2D58F81Q33804626-38EFCFAE-41E1-4861-95E6-D376A1307BC8Q34166602-31F7C423-E657-4AAA-A9C8-CA5AEF63C18FQ34288454-DA3049E6-0F79-4FA7-8BE4-7C43EFEFA305Q34330047-41BED622-DF19-4D88-9664-EDB5DF73126AQ35058504-919869FB-B61B-4CFD-8B6C-1FA85112A3E7Q35402927-C90A0741-066C-403A-B9EF-956E5E2DBA0EQ35551957-196E2BAA-3F6F-45C7-99D6-3BC99CC11FA5Q35738744-2657FC45-4E4E-4CA6-9ADE-AC5C98DF091CQ36004284-0B9C4F33-90CF-4FB5-B7D7-F5E3065E996AQ36617600-DF2976BF-2259-4DE0-A46D-F1FA7EE8EC80Q36895350-50E9DBDD-F15C-4945-9FD9-A28234DB59E7Q37006834-FD33AAB5-8A92-4370-BAEE-0CF2EDC2AE51Q37107988-439DF349-096D-457E-94C9-6B639653D80FQ37207673-CF0E38F7-8D25-41A6-AD3B-3255D95FA533Q37224604-E540C959-D4EC-4598-A4CD-05E7DC8DFA38Q37486513-36C00B46-E389-49B0-A5E7-12C25B99C750Q37515995-C9ECA32D-66AF-47BD-9CBE-9C901A95DC0FQ37524192-8AA977E0-C077-4409-97A6-2D15A86B370AQ37598468-D4DEA9EC-B488-441D-A9C1-169BBF0952A0Q37606424-ED61DFAA-758F-4324-9638-E8DDDC16D229Q37667998-67DF9B4B-8C5A-47C7-8184-35993518F094Q37845178-18585E06-E52D-448C-A4D8-E78D5F42CCE3Q37980218-E17EA6E5-3827-4992-9DB6-D485BFF6FA50Q38309098-82B9CC43-CF39-499E-8FEC-77A8F0A212FAQ38720370-90BBCF50-F40A-46AC-BFC1-36545F4ACCF7Q38742868-CCACECAB-041B-4AC0-910E-F1CE82BFE5D4Q38762992-FEFF8BC2-CD2D-497D-8434-52FBC1094FD8Q38783775-8EBA2278-13A2-4E11-83FE-87B8203FF20EQ38821761-3320D5E0-88E7-4EFA-8D05-D6C7FFD87ECAQ38844916-A8ABA25E-CBA7-4791-A46A-3A68F7A084E4
P50
description
researcher ORCID: 0000-0002-5263-8386
@en
wetenschapper
@nl
name
Antonio Rosato
@ast
Antonio Rosato
@en
Antonio Rosato
@es
Antonio Rosato
@nl
type
label
Antonio Rosato
@ast
Antonio Rosato
@en
Antonio Rosato
@es
Antonio Rosato
@nl
prefLabel
Antonio Rosato
@ast
Antonio Rosato
@en
Antonio Rosato
@es
Antonio Rosato
@nl
P1053
E-8626-2010
P106
P1153
35243368500
P1343
P21
P31
P3829
P496
0000-0002-5263-8386
P569
1964-01-01T00:00:00Z